Tumour heterogeneity was associated with treatment when evaluating GGG, PTEN and the combined biomarker at the diagnostic procedure (p = 0.048, p = 0.041 and p = 0.033, respectively), and when considering either biomarker at the last procedure before any treatment (p < 0.0001 for GGG, p = 0.0017, for DNA ploidy, p = 0.0057 for PTEN and p = 0.0009 for the combined biomarker), (Supplementary Table S5). The gene discussed is PTEN; the disease is neoplasm.